Organon & Co.

Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs

MAGA PAC received Roivant stock, Ramaswamy and Musk to retain ownership of biotechs

Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves

Deals Report: Novo Nordisk tapping NanoVation delivery tech, Organon acquires Dermavant, Telix expands U.S. radiopharma footprint, and more

Plus: Medivation vet Hung now chair of T-Therapeutics and updates from Voyager and Eyenuk

Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira

Samsung Bioepis report says Humira has 97% of the adalimumab market almost a year after it lost exclusivity

Plus: Arjona Ferreira named CMO at Organon, and updates from Convergent, Purespring, Nanobiotix, Enzo, FibroGen, Engitix and more

Previewing Back to School 2023: Trajectories of public biotechs across market cap tiers — long-term and short-term trends

Less than 10 companies taking a shot at PCOS. With each testing a different MoA, they promise broad learnings